News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vicor Technologies, Inc.' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com



6/6/2011 1:15:34 PM

BOCA RATON, Fla., June 6, 2011 /PRNewswire/ -- Vicor Technologies, Inc. (OTCBB: VCRT) today announced that CEO David H. Fater's June 2nd RetailInvestorConferences.com presentation is now available for on-demand viewing. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer, an innovative, non-invasive diagnostic used to risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

LINK: www.retailinvestorconferences.com > Click the red "register/watch event now" button.

Mr. Fater's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About RetailInvestorConferences.com

RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire, and MUNCmedia is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network, and MUNCmedia's sophisticated retail investor targeting.

About Vicor Technologies, Inc.

Vicor Technologies' PD2i Analyzer employs its patented, proprietary point correlation dimension algorithm (PD2i®), a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. Vicor anticipates use of its PD2i Analyzer to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

SOURCE Vicor Technologies, Inc.


Read at BioSpace.com


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES